179 related articles for article (PubMed ID: 8269592)
21. Poly-isoprenylated ifosfamide analogs: Preactivated antitumor agents as free formulation or nanoassemblies.
Skarbek C; Delahousse J; Pioche-Durieu C; Baconnais S; Deroussent A; Renevret P; Rivard M; Desmaele D; Martens T; Le Cam E; Couvreur P; Paci A
Int J Pharm; 2017 Nov; 532(2):748-756. PubMed ID: 28546071
[TBL] [Abstract][Full Text] [Related]
22. Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects.
Delahousse J; Skarbek C; Desbois M; Perfettini JL; Chaput N; Paci A
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32784216
[TBL] [Abstract][Full Text] [Related]
23. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
Silies H; Blaschke G; Hohenlöchter B; Rossi R; Jürgens H; Boos J
Int J Clin Pharmacol Ther; 1998 May; 36(5):246-52. PubMed ID: 9629987
[TBL] [Abstract][Full Text] [Related]
24. Stem cell toxicity of oxazaphosphorine metabolites in comparison to their antileukemic activity.
Brueggemann SK; Schlenke P; Klich S; Deeken M; Peters SO; Wagner T
Biochem Pharmacol; 2002 Apr; 63(7):1337-41. PubMed ID: 11960610
[TBL] [Abstract][Full Text] [Related]
25. In vitro metabolism of tirilazad mesylate in male and female rats. Contribution of cytochrome P4502C11 and delta 4-5 alpha-reductase.
Wienkers LC; Steenwyk RC; Mizsak SA; Pearson PG
Drug Metab Dispos; 1995 Mar; 23(3):383-92. PubMed ID: 7628305
[TBL] [Abstract][Full Text] [Related]
26. Metabolism and pharmacokinetics of oxazaphosphorines.
Boddy AV; Yule SM
Clin Pharmacokinet; 2000 Apr; 38(4):291-304. PubMed ID: 10803453
[TBL] [Abstract][Full Text] [Related]
27. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.
Roy P; Yu LJ; Crespi CL; Waxman DJ
Drug Metab Dispos; 1999 Jun; 27(6):655-66. PubMed ID: 10348794
[TBL] [Abstract][Full Text] [Related]
28. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy.
Kurowski V; Wagner T
Cancer Chemother Pharmacol; 1993; 33(1):36-42. PubMed ID: 8269587
[TBL] [Abstract][Full Text] [Related]
29. Gender difference in ifosfamide metabolism by human liver microsomes.
Schmidt R; Baumann F; Hanschmann H; Geissler F; Preiss R
Eur J Drug Metab Pharmacokinet; 2001; 26(3):193-200. PubMed ID: 11695720
[TBL] [Abstract][Full Text] [Related]
30. Mutagenic activity of cyclophosphamide, ifosfamide, and trofosfamide in different genes of escherichia coli and salmonella typhimurium after biotransformation through extracts of rodent liver.
Ellenberger J; Mohn G
Arch Toxicol; 1975; 33(3):225-40. PubMed ID: 1096853
[TBL] [Abstract][Full Text] [Related]
31. Oxidative metabolism of butylated hydroxytoluene by hepatic and pulmonary microsomes from rats and mice.
Thompson JA; Malkinson AM; Wand MD; Mastovich SL; Mead EW; Schullek KM; Laudenschlager WG
Drug Metab Dispos; 1987; 15(6):833-40. PubMed ID: 2893710
[TBL] [Abstract][Full Text] [Related]
32. [Isolation and characterisation of two main metabolites of ifosfamide from human urine (author's transl)].
Norpoth K; Müller G; Raidt H
Arzneimittelforschung; 1976; 26(7):1376-7. PubMed ID: 1036928
[TBL] [Abstract][Full Text] [Related]
33. Metabolism and transport of oxazaphosphorines and the clinical implications.
Zhang J; Tian Q; Yung Chan S; Chuen Li S; Zhou S; Duan W; Zhu YZ
Drug Metab Rev; 2005; 37(4):611-703. PubMed ID: 16393888
[TBL] [Abstract][Full Text] [Related]
34. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.
Brock N; Stekar J; Pohl J; Niemeyer U; Scheffler G
Arzneimittelforschung; 1979; 29(4):659-61. PubMed ID: 114192
[TBL] [Abstract][Full Text] [Related]
35. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy.
Chen L; Waxman DJ
Cancer Res; 1995 Feb; 55(3):581-9. PubMed ID: 7834628
[TBL] [Abstract][Full Text] [Related]
36. Metabolism of the calcium antagonist, mibefradil (POSICOR, Ro 40-5967). Part II. Metabolism in hepatic microsomes from rat, marmoset, cynomolgus monkey, rabbit and man.
Wiltshire HR; Sutton BM; Heeps G; Betty AM; Angus DW; Madigan MJ; Sharp SR
Xenobiotica; 1997 Jun; 27(6):539-56. PubMed ID: 9211655
[TBL] [Abstract][Full Text] [Related]
37. Ifosfamide or trofosfamide in patients with intraocular lymphoma.
Jahnke K; Thiel E; Bechrakis NE; Willerding G; Kraemer DF; Fischer L; Korfel A
J Neurooncol; 2009 Jun; 93(2):213-7. PubMed ID: 19099202
[TBL] [Abstract][Full Text] [Related]
38. Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide.
Preiss R; Schmidt R; Baumann F; Hanschmann H; Hauss J; Geissler F; Pahlig H; Ratzewiss B
J Cancer Res Clin Oncol; 2002 Jul; 128(7):385-92. PubMed ID: 12136253
[TBL] [Abstract][Full Text] [Related]
39. In vitro metabolism study of combretastatin A-4 in rat and human liver microsomes.
Aprile S; Del Grosso E; Tron GC; Grosa G
Drug Metab Dispos; 2007 Dec; 35(12):2252-61. PubMed ID: 17890446
[TBL] [Abstract][Full Text] [Related]
40. Differential in vitro hepatic and intestinal metabolism of ifosfamide in the rat.
Lu H; Chan KK
Xenobiotica; 1998 Aug; 28(8):779-84. PubMed ID: 9741956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
